You can buy or sell KemPharm and other stocks, options, ETFs, and crypto commission-free!
KemPharm, Inc. Common Stock, also called KemPharm, is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. Read More It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.
52 Week High
52 Week Low
Seeking AlphaMar 18
KemPharm: Will Optimism Win?
However, a KP415 deal remains the primary value driver for KMPH stock. It will solve KemPharm's cash burn question, and maybe put some cash into the company's bank account. First, I'd like to write a few words about the presentation on Apadaz commercialization progress given on Wednesday 3/13, and then move to KP415, an ADHD prodrug that is KemPharm's flagship product. The Apadaz Update For readers just joining the discussion, Apadaz is a hydrocodone/acetaminophen prodrug that is designed to limit abuse ...
Seeking AlphaMar 13
KemPharm down 6% premarket on Apadaz coverage update
Thinly traded nano cap KemPharm (NASDAQ:KMPH) slips 6% premarket, albeit on only 420 shares, on the heels of its update on formulary adoption of pain med APADAZ (benzhydrocodone and acetaminophen).
Seeking AlphaFeb 28
KemPharm (KMPH) CEO Travis Mickle on Q4 2018 Results - Earnings Call Transcript
KemPharm (NASDAQ:KMPH) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Jason Rando - Investor Relations, Tiberend Strategic Advisors, Inc. Travis Mickle - President & Chief Executive Officer LaDuane Clifton - Chief Financial Officer Rusty Johnson - Chief Business Officer Conference Call Participants Dan Busby - RBC Capital Markets Scott Henry - Roth Capital Partners Operator Good day, ladies and gentlemen, and welcome to the KemPharm Fourth Quarter and Year End 2...
Expected May 9, After Hours